Oxford, United Kingdom

Wooi Fang Lim

This inventor holds 1 USPTO granted patent. Top assignee: Oxford University Innovation Ltd. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wooi Fang Lim. Retrieved from https://idiyas.com/inventor/wooi-fang-lim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wooi Fang Lim: Innovator in Muscular Atrophy Treatment

Introduction

Wooi Fang Lim is a notable inventor based in Oxford, GB. He has made significant contributions to the field of medical research, particularly in the treatment of spinal and bulbar muscular atrophy. His innovative approach focuses on modulating the levels of a naturally occurring androgen receptor variant.

Latest Patents

Lim holds a patent for the treatment of AR-related disorders. This invention relates to the modulation of AR2 levels, which is capable of influencing androgen receptor transcriptional activity. His work in this area has the potential to advance therapeutic options for individuals affected by these disorders. He has 1 patent to his name.

Career Highlights

Wooi Fang Lim is associated with Oxford University Innovation Limited, where he continues to engage in groundbreaking research. His career is marked by a commitment to improving the lives of those suffering from muscular atrophy through innovative treatments.

Collaborations

Lim has collaborated with esteemed colleagues, including Carlo Rinaldi and Matthew Wood. These partnerships have fostered a collaborative environment that enhances the research and development of effective treatments.

Conclusion

Wooi Fang Lim's contributions to the treatment of spinal and bulbar muscular atrophy highlight his role as an innovator in the medical field. His work not only advances scientific understanding but also offers hope for improved therapies for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…